May 16, 2023 02:22 PM EDT
Pharma
Manufacturing

Ip­ca Lab­o­ra­to­ries cit­ed for qual­i­ty is­sues at In­dia fa­cil­i­ty that pro­duces API

Tyler Patchen

News Reporter

The FDA iden­ti­fied sev­er­al qual­i­ty is­sues at a plant in In­dia owned by Ip­ca Lab­o­ra­to­ries that makes ac­tive phar­ma­ceu­ti­cal in­gre­di­ents.

In the

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

No­vavax re­sponds to FDA’s tri­al ask, with Covid vac­cine strain up­dates un­der scruti­ny

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times